Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2015; 04(04): 186-188
DOI: 10.4103/2278-330X.175958
MYELODYSPLASTIC SYNDROME : Review Article

Role of iron chelation in improving survival: An integral part of current therapy for myelodysplastic syndromes

Sachi Jain Taran
Department of Pediatrics, SAIMS, Indore, Madhya Pradesh
,
Rakesh Taran
Department of Oncology, MGM Medical College, Indore, Madhya Pradesh
› Author Affiliations Source of Support: Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

This review article highlights the current role of iron chelation in MDS to optimize survival and quality of life. Its role in specific subtypes of MDS is also discussed.

Key words

Myelodysplastic syndromes - overload - quality of life - survival


Publication History

Article published online:
31 December 2020

© 2015. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Zeidan AM, Linhares Y, Gore SD. Current therapy of myelodysplastic syndromes. Blood Rev 2013;27:243-59.
  • 2 Kantarjian H, O′Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-61.
  • 3 Faltas B, Zeidan A, Gergis U. Myelodysplastic syndromes: Toward a risk-adapted treatment approach. Expert Rev Hematol 2013;6:611-24.
  • 4 Leitch HA. Controversies surrounding Iron chelation therapy for MDS. Blood Rev 2013;27:243-59.
  • 5 Steensma DP, Bennett JM. The myelodysplastic syndromes: Diagnosis and treatment. Mayo Clin Proc 2006;81:104-30.
  • 6 Taran SJ, Taran R. Role of iron chelation in Thalassaemia and Iron overload. Indian J Med Sci 2014.
  • 7 Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011;96:1433-40.
  • 8 Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MT, et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: A GITMO study. Haematologica 2010;95:476-84.
  • 9 Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008;88:24-9.
  • 10 Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003;120:187-200.
  • 11 Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: Regulation of Mammalian iron metabolism. Cell 2010;142:24-38.
  • 12 Gattermann N. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional Iron overload. Leuk Res 2007;31 Suppl 3:S10-5.
  • 13 De Domenico I, Ward DM, Kaplan J. Specific iron chelators determine the route of ferritin degradation. Blood 2009;114:4546-51.
  • 14 Cermak J, Kacirkova P, Mikulenkova D, Michalova K. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk Res 2009;33:1469-74.
  • 15 Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007;78:487-94.
  • 16 Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010;28:2847-52.
  • 17 Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin 2009;25:139-47.
  • 18 Hankins JS, McCarville MB, Loeffler RB, Smeltzer MP, Onciu M, Hoffer FA, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 2009;113:4853-5.
  • 19 Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One 2011;6:e23109.
  • 20 Leitch HA, Chan C, Leger CS, Foltz LM, Ramadan KM, Vickars LM. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. Leuk Res 2012;36:1380-6.
  • 21 Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res 2010;34:864-70.
  • 22 Neukirchen J, Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, et al. Improved survival in MDS patients receiving iron chelation therapy - A matched pair analysis of 188 patients from the Düsseldorf MDS registry. Leuk Res 2012;36:1067-70.
  • 23 Temraz S, Santini V, Musallam K, Taher A. Iron overload and chelation therapy in myelodysplastic syndromes. Crit Rev Oncol Hematol 2014;91:64-73.
  • 24 Gattermann N, Finelli C, Porta MD. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res 2010;34:1143-50.
  • 25 Breccia M, Finsinger P, Loglisci G, Federico V, Santopietro M, Colafigli G, et al. Deferasirox treatment for myelodysplastic syndromes: "Real-life" efficacy and safety in a single-institution patient population. Ann Hematol 2012;91:1345-9.
  • 26 Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996;94:288-99.
  • 27 Gattermann N, Finelli C, Della Porta M. Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. Haematologica 2012;97:1364-71.
  • 28 Cilloni D, Messa E, Biale L. High rate of erythroid response during iron chelation therapy in a cohort of 105 patients affected by hematologic malignancies with transfusional iron overload: An Italian multicenter retrospective study. ASH Annu Meet Abstr 2011;118:611.
  • 29 Armand P, Sainvil MM, Kim HT, Rhodes J, Cutler C, Ho VT, et al. Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant 2013;48:146-7.
  • 30 Mitchell M, Gore SD, Zeidan AM. Iron chelation therapy in myelodysplastic syndromes: Where do we stand? Expert Rev Hematol 2013;6:397-410.
  • 31 Breccia M, Alimena G. Efficacy and safety of deferasirox in myelodysplastic syndromes. Ann Hematol 2013;92:863-70.